Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

In Figures 1C and1D, the fulvestrant KM curves are same as the curves in panels A and B. Figure 1C and 1D have been replaced.